PSA dosage remains the milestone for PCa detection, however, the predictive value of PSA is drastically reduced in those men with PCa suspicion, candidates for SLI; in this subgroup of subjects, only about 60% really have a confirmed PCa diagnosis, making necessary the identification of other complementary biomarkers. This evidence concerns the gene KLK3 and posterior cortical atrophy.